Status:
COMPLETED
Study Evaluating Single Ascending Doses Of ILS-920
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration o...
Eligibility Criteria
Inclusion
- Men or women of nonchildbearing potential
- Aged 18 to 50 years inclusive at screening.
Exclusion
- Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
- History of drug abuse within 1 year before study day 1.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00827190
Start Date
February 1 2009
End Date
July 1 2009
Last Update
February 3 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.